title: Increased dose-intensity of gemcitabine in advanced non small cell lung cancer (NSCLC): a multicenter phase II study in elderly patients from the "polmone toscano group" (POLTO).
abstract: Gemcitabine is usually administered at a planned dose-intensity (DI) from 750 to 800 mg/m2/week. Preclinical data have suggested a possible dose-response relationship of gemcitabine. A multicenter phase II study was conducted to evaluate the activity in terms of no progression rate (complete responses+partial responses+stable diseases) of gemcitabine administered at an increased DI (1000 mg/m2/week) in elderly advanced non-small-cell lung cancer (NSCLC) patients. Secondary endpoints were to evaluate tolerability, progression free survival and overall survival. Elderly (age>or=70 years) chemo-naive advanced NSCLC patients, ECOG PS 0-2, were treated with intravenous gemcitabine 1500 mg/m2 intravenous (30 min infusion) on days 1 and 8 every 21 days for four courses. One hundred and twenty-two patients with a median age of 75 years (range 70-84) entered the study. The following grade 3 (NCI-CTC) haematological toxicities were reported (percent of patients): neutropenia 2.4%, thrombocytopenia 1.6%, anaemia 2.4%. No grades 3-4 non-haematological toxicities were observed. Among 111 evaluable patients 52 (46.8%) no progressions, 17 (15.3%) partial responses (WHO criteria), 35 (31.5%) stable diseases and 59 (53.2%) progressions were observed. Median time to progression was 3.2 months and median duration of survival was 5.4 months. The overall 1-year survival rate was 27%. Although increased dose-intensity of gemcitabine in elderly NSCLC patients is feasible without severe toxicities, this does not seem to be associated with an increased activity and efficacy in comparison to standard gemcitabine regimens with lower dose-intensities.
authors.affiliation: Division of Medical Oncology, Department of Oncology, Livorno, Italy. tiby@katamail.com
authors.forename: C
authors.initials: C
authors.lastname: Tibaldi
authors.forename: S
authors.initials: S
authors.lastname: Ricci
authors.forename: F
authors.initials: F
authors.lastname: Russo
authors.forename: I
authors.initials: I
authors.lastname: Bernardini
authors.forename: L
authors.initials: L
authors.lastname: Galli
authors.forename: A
authors.initials: A
authors.lastname: Chioni
authors.forename: C
authors.initials: C
authors.lastname: Orlandini
authors.forename: A M
authors.initials: AM
authors.lastname: Grosso
authors.forename: A Lopes
authors.initials: AL
authors.lastname: Pegna
authors.forename: A
authors.initials: A
authors.lastname: Fabbri
authors.forename: F
authors.initials: F
authors.lastname: Innocenti
authors.forename: K
authors.initials: K
authors.lastname: Ferrari
authors.forename: L
authors.initials: L
authors.lastname: Tognarini
authors.forename: P F
authors.initials: PF
authors.lastname: Conte
authors.forename: A
authors.initials: A
authors.lastname: Falcone
mesh_terms: D000367:Age Factors; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology*; D003841:Deoxycytidine / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D008297:Male; D009503:Neutropenia / Q000139:chemically induced; D016019:Survival Analysis; D013921:Thrombocytopenia / Q000139:chemically induced; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine